Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of NovaMed, Inc. (“NovaMed” or the “Company”) (Nasdaq: NOVA) relating to the proposed acquisition by an affiliate of the private equity investment firm H.I.G. Capital in a transaction valued at approximately $214 million, including assumed debt.

Under the terms of the offer, NovaMed shareholders would receive cash of $13.25 for each share of NovaMed stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of NovaMed by not acting in NovaMed shareholders' best interests in connection with the sale process to H.I.G. Capital. The transaction appears to be unfair, in part, given the share price offered to NovaMed shareholders. In contrast to the offer price of $13.25, the 52 week high for the Company’s shares was $16.41 and at least one analyst has set a target price for NovaMed at $18.00.

If you own shares of NovaMed and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, or by calling toll free 877-LEGAL-90.

Novamed (NASDAQ:NOVA)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Novamed Charts.
Novamed (NASDAQ:NOVA)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Novamed Charts.